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Identity 
Other names: EC 2.7.10.1; ETK; ETK1; EphA3; 
HEK; HEK4; TYRO4 
HGNC (Hugo): EPHA3 
Location: 3p11.2 
Local order: (tel) C3orf38 (ENSG00000179021) ->, 
949,562bp, EPHA3 (374,609bp) ->, 720,071bp, <- 
AC139337.5 (ENSG00000189002) (cen) 
Note 
EPHA3 is flanked by two gene deserts. 
DNA/RNA 
Note 
EPHA3 spans the human tile path clones CTD-
2532M17, RP11-784B9 and RP11-547K2. 
Description 
EPHA3 consists of 17 exons and 16 introns and spans 
375kb of genomic DNA. It is the second largest of the
EPH genes after EPHA6. 
 
 
Figure 1: Chromosomal location of EPHA3 (based on Ensembl Homo sapiens version 53.36o (NCBI36)). 
Figure 2: Genomic neighbourhood of EPHA3 (based on Ensembl Homo sapiens version 53.36o (NCBI36)). 
 
Figure 3: Genomic organisation of EPHA3. 
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Transcription 
Two alternatively spliced transcript variants have been 
described (NM_005233.5, a 5,807 nucleotide mRNA 
and NM_182644.2, a 2,684 nucleotide mRNA). The 
shorter transcript results in truncation within the 
extracellular domain of EphA3 and is predicted to 
produce a soluble protein. The 5' end of EPHA3 is 
associated with a CpG island, a feature common to all 
EPH genes. The EPHA3 promoter also lacks a TATA 





The Eph receptors constitute the largest of the 20 
subfamilies of human receptor tyrosine kinases. The
founding member of this group was isolated originally 
from an erythropoietin producing hepato-ma cell line. 
 
Figure 4: Domain organisation of EphA3. 
Description 
The EPHA3 gene encodes a 983 amino acid protein 
with a calculated molecular weight of 110.1kDa and  
isoelectric point of 6.7302. Amino acids 1-20 constitute 
a signal peptide. The predicted mole-cular mass of the 
translated protein minus the signal peptide is 92.8kDa. 
The 521 amino acid extra-cellular domain contains fve
potential sites for N-glycosylation such that EphA3 is 
typically detected as a 135kDa glycoprotein. This 
mature isoform of EphA3 is a single-pass 
transmembrane receptor tyrosine kinase. At its N-
terminus is a 174 amino acid ligand binding domain,  
14 amino acid EGF-like domain and two membrane 
proximal fibro-nectin type III repeats. Amino acids 21-
376 of the extracellular domain also are rich in cysteine 
residues. The intracellular domain contains the tyrosine 
kinase domain and a sterile alpha motif. EphA3 lacks a 
PDZ domain interacting motif present in EphA7, 
EphB2, EphB3, EphB5 and EphB6. Activation of the 
EphA3 receptor tyrosine kinase domain is associated 
with two tyrosine residues in the juxtamembrane region 
(Y596, Y602) that are sites of autophosphorylation and 
interact with the kinase domain to modulate its activity. 
EphA3 belongs to an evolutionarily ancient subfamily 
of receptor tyrosine kinases with mem-bers being 
present in sponges, worms and fruit flies. The 
expansion in the number of Eph receptor-encoding 
genes along with genes encoding their ligands, the 
ephrins (Eph receptor interacting proteins), is proposed 
to have contributed to the increase in complexity of the 
bilaterian body plan. Genes encoding EphA3 are found 
in the genomes of representative members of at leas
five of the seven classes of vertebrates including bony 
fish (zebrafish, pufferfish, medaka), amphibians 
(African clawed frog), reptiles (green anole lizard), 
birds (chicken) and mammals (platypus, possum, 
human). 
Fourteen Eph receptors have been identified in 
vertebrates. These are subdivided into either EphA 
(EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, 
EphA7, EphA8, EphA10) or EphB (EphB1, EphB2, 
EphB3, EphB4, EphB6) subclasses which differ 
primarily in the structure of their ligand binding 
domains. EphA receptors also exhibit greater affinity 
for binding GPI-linked ephrin-A ligands while EphB 
receptors bind transmembrane ephrin-B ligands. While 
interactions are somewhat promis-cuous, and some 
cross-class binding occurs, each Eph receptor display  
distinct affinity for the different ephrin ligands. The 
high affinity ligands for EphA3 are ephrin-A2 and 
ephrin-A5. EphA3 also binds ephrin-A3 and ephrin-A4 
with lower affinity. 
Eph-ephrin binding involves contact between cells. 
Upon binding, receptor-ligand dimers form 
heterotetramers, which further assemble into higher 
order signalling clusters. Several moieties in the EphA3 
receptor extracellular region mediate ephrin binding. A 
high-affinity binding site in the N-terminal ephrin 
binding domain mediates inter-cellular Eph-ephrin 
interaction. Two additional lower-affinity ephrin-
binding sites, one in the ephrin-binding domain andthe 
other in the cysteine-rich region, are involved in 
clustering of Eph-ephrin complexes. 
Following ephrin-A5-mediated EphA3 receptor 
clustering, intracellular signalling by EphA3 receptors 
is initiated by autophosphorylation of three defined 
tyrosine residues, two in the highly conserved 
juxtamembrane region and the third in the activation 
loop of the kinase domain (Y779). Rapid reorganisation 
of the actin and myosin cytoskeleton follows, leading 
to retraction of cellular protrusions, membrane 
blebbing and cell detachment, following association of 
the adaptor protein CrkII with tyrosine phosphorylated 
EphA3 and activation of RhoA signalling. 
Such Eph-ephrin interaction triggers bidirectional 
signalling, that is signalling events within both Eph- 
and ephrin-bearing cells, an unusual phenomenon for 
receptor tyrosine kinases, most of which interact with 
soluble ligands. Subsequently, depending on the 
cellular context (including the identity of the 
interacting Eph-ephrin receptor-ligand pairs, their 
relative levels on interacting cells, the presence of 
additional Ephs and ephrins and their alternative  
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isoforms, and the net effect of interaction with 
additional signalling pathways) this either results in 
repulsion or promotes adhesion of the interacting cells. 
Cellular repulsion and the termination of Eph-ephrin 
signalling require disruption of the receptor-ligand 
complex. This is brought about either by enzymatic 
cleavage of the tethered ephrin ligand in cis or in tra s 
or by endocytosis of Eph-ephrin complexes. EphA3-
ephrin-A2 receptor-ligand complexes are shed from 
ephrin-A2 bearing cells following receptor-ligand 
binding when ADAM10 (a disintegrin and 
metalloprotease 10), associated with ephrin-A2, cleaves 
ephrin-A2. Conversely, intercellular EphA3-ephrin-A5 
receptor-ligand complexes are broken when EphA3-
associated ADAM10 cleaves ephrin-A5 on opposing 
cells, following binding to EphA3. The post-cleavage 
ephrin-A5-EphA3 complex is then endocytosed by the 
EphA3-expressing cell. 
While cellular repulsion is often the outcome of Eph-
ephrin interaction, in some circumstances adhesion 
may persist. For example, ADAM10 has been observed 
not to cleave ephrin-A5 following EphA3-ephrin-A5 
interaction involving LK63 cells in which high 
intracellular protein tyrosine phosphatase activity also 
appears to counter ephrin-A5 stimulated 
phosphorylation of EphA3, holding the receptor in an 
inactive, unphosphorylated state. Also cis interaction 
between EphA3 and ephrin-A2 expressed on the same 
cell surface has been reported to block EphA3 
activation by ephrins acting in trans, the cis interaction 
site being independent of the ligand binding domain. 
Another mechanism that may favour stable cell-cell 
adhesion involves truncated Eph receptor isoforms 
acting in a dominant negative manner. While activation 
of full length EphA7 by ephrin-A5 results in cellular 
repulsion, ephrin-A5-induced phosphorylation of 
EphA7 is inhibited by two EphA7 splice variants with 
truncated kinase domains and adhesion results. A splice 
variant of EPHA3 also has been reported and is 
predicted to give rise to a soluble isoform of EphA3. 
Whether this soluble variant of EphA3, which is 
truncated before the transmembrane domain, functions 
in a similar manner to the shorter EphA7 isoforms ha
not been established. 
While important details of EphA3 signalling have been 
determined, more complete understanding of EphA3 
activity will require knowledge of the full complement 
of EphA3 interacting proteins. Substrates that are 
targets for the tyrosine kinase activity of EphA3 have 
yet to be defined and potential mediators or modulators 
of EphA3 signalling output such as Src family kinases, 
additional phosphotyrosine binding adaptors, SAM 
domain interacting factors, interaction with other 
receptor kinases and crosstalk with other signalling 
pathways, and the regulatory role of phosphatases all 
remain to be explored. Based on the range of 
interacting proteins identified for other Eph receptors 
(some common to more than one Eph, others 
apparently unique to individual Ephs) additional 
effectors of EphA3 signalling output are likely. 
Expression 
EphA3 was first identified as an antigen expressed at 
high levels (10,000-20,000 copies per cell) on the 
surface of the LK63 pre-B cell acute lymphoblastic 
leukaemia cell line. It also was found to be expressed 
by JM, HSB-2 and MOLT-4 T-cell leukaemic cell 
lines, in CD28-stimulated Jurkat cells, and in 16 of 42 
cases of primary T-cell lymphoma (but not normal 
peripheral T lymphocytes nor in any subset of thymus-
derived developing T cells), as well as at low frequ ncy 
in acute myeloid leukaemia and chronic lymphocytic 
leukaemia EphA3 is not expressed by many other 
haematopoietic cell lines. 
Subsequently, EphA3 expression has been shown to be 
most abundant, and also highly regulated both 
temporally and spatially, during vertebrate 
development. Prominent EphA3 expression occurs in 
the neural system, including the retinal ganglion cells 
of the embryonic retina in a graded distribution from 
anterior/nasal (lowest) to posterior /temporal (highest); 
the cerebrum, thalamus, striatum, olfactory bulb, 
anterior commissure, and corpus callosum of the 
forebrain; and the medial motor column ventral motor 
neurons of the spinal cord; and extraneurally by 
mesodermally-derived tissues including the paraxial 
musculature, tongue musculature, submucosa of the 
soft palate, capsule of the submandibular gland, cortical 
rim of bone, thymic septae, media of the pharynx, 
trachea, great vessels, small intestine and portal vein, 
cardiac valves, and the renal medulla. In adult tissue  
EphA3 expression is more restricted and detected at 
significantly lower levels than during early 
development. 
Localisation 
Isoform 1: Cell membrane; single-pass type I 
membrane protein. 
Isoform 2: Secreted. 
Function 
Eph receptors modulate cell shape and movement 
through reorganisation of the cytoskeleton and changes 
in cell-cell and cell-substrate adhesion, and are 
involved in many cellular migration, sorting (tissue 
patterning) and guidance events, most often during 
development, and in particular involving the nervous 
system. There is evidence too that Eph receptor 
signalling influences cell proliferation and cell-fate 
determination and growing recognition that Eph 
receptors function in adult tissue homeostasis. 
EphA3 is thought to play a role in retinotectal mapping, 
the tightly patterned projection of retinal ganglion cell 
axons from the retina to the optic tectum (or superior 
colliculus in mammals). In chicks, posterior retinal 
ganglion axons expressing highest levels of EphA3 
project to the anterior tectum where the graded  
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expression of ephrin-A2 and ephrin-A5 is lowest and 
are excluded from projecting more posteriorly where 
ephrin-A2/A5 expression is highest. More direct 
evidence of non-redundant function for EphA3 has 
come from phenotypic analysis of EphA3 knockout 
mice. Approximately 70-75% of EphA3 null mice die 
within 48 hours of birth with post-mortem evidence of 
pulmonary oedema secondary to cardiac failure. These 
mice exhibit hypoplastic atrioventricular endocardil 
cushions and subsequent atri-oventricular valve and
atrial membranous septal defects, with endocardial 
cushion explants from these mice giving rise to fewer 
migrating cells arising from epithelial to mesenchymal 
trans-formation. Expression of EphA3 in the spinal 
cord appears to be redundant as axial muscle targeting 
by medial motor column motor axons and the 
organisation of the motor neuron columns is not 
altered. EphA4 is the only other EphA receptor also 
expressed by developing spinal cord motor neurons and 
in mice lacking EphA3 and EphA4 these receptors 
together repel axial motor axons from neighbouring 
ephrin-A-expressing sensory axons, inhibiting 
intermingling of motor and sensory axons and 
preventing mis-projection of motor axons into the 
dorsal root ganglia. In contrast to the chick, EphA3 is 
not expressed by mouse retinal ganglion cells. Instead 
the closely related receptors EphA5 and EphA6 (see 
homology below) are expressed in a low nasal to high 
temporal gradient. However, if EphA3 is ectopically 
expressed in retinal ganglion cells in mice these axons 
project to more rostral positions in the superior 
colliculus. 
A function for soluble EphA3 has not been reported 
although potentially this isoform might play a role in 
promoting cell adhesion (see above) or act as a tumour 
suppressor protein (see below). 
Homology 
Phylogenetic tree for the Eph receptors. Amino acid 
sequences used for this compilation were EphA1 
(NP_005223), EphA2 (NM_004431), EphA3  
(NP_005224), EphA4 (NP_004429), EphA5 
(NM_004439), EphA6 (ENSP00000374323), EphA7 
(NP_004431), EphA8 (NP_065387), EphA10 
(NP_001092909), EphB1 (NP_004432), EphB2 
(NP_004433), EphB3 (NP_004434), EphB4 




Seven nonsynonymous single nucleotide polymer-
phisms (all missense) are recorded in the dbSNP 
database for EPHA3. Recognised allelic variation 
occurs for the following EphA3 amino acids: I564V 
(rs56081642), C568S (rs56077781), L590P 
(rs56081642), T608A (rs17855794), G777A 
(rs34437982), W924R (rs35124509) and H914R 
(rs17801309). 
Germinal 
To date no germinal mutations in EPHA3 have been 
associated with disease. 
Somatic 
Somatic mutations in EPHA3 have been detected in 
lung adenocarcinoma (T166N, G187R, S229Y, 
W250R, M269I, N379K, T393K, A435S, D446Y, 
 
Figure 6: Sites of somatic mutations in EphA3 identified in lung adenocarcinoma colorectal carcinoma, glioblastoma multiforme and 
metastatic melanoma. 
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S449F, G518L, T660K, D678E, R728L, K761N, 
G766E, T933M), colorectal carcinoma (T37K, N85S, 
I621L, S792P, D806N), glioblastoma multi-forme 




EPHA3 was among the genes whose expression was 
upregulated during androgen-independent progresssion 
in an LNCaP in vitro cell model of prostate cancer. 
Melanoma 
Note 
A melanoma patient with an especially favourable 
evolution of disease, associated with a very strong a d 
sustained anti-tumour cytotoxic T lymphocyte 
response, was found to have a lytic CD4 clone that 
recognised an EphA3 antigen presented by the HLA 
class II molecule HLA- DRB1*1101. 94% (75 of 80) of 
melanomas examined expressed EphA3 in contrast to 
normal melanocytes which do not express detectable 
EphA3. 
Lung cancer, Sarcoma, and Renal cell 
carcinoma 
Note 
44% (11 of 25) of small cell lung cancer, 24% (10 of 
41) of non-small cell lung cancer, 58% (17 of 29) of 
sarcomas, and 31% (12 of 38) of renal cell carcinomas 
expressed EphA3 at levels significantly higher than the 
corresponding normal tissues. 
Breakpoints 
Note 
No reported breakpoints identified to date nor 
recognised fusion proteins involving EphA3. 
To be noted 
Note 
Soluble forms of EphA3 appear to inhibit tumour 
angiogenesis and tumour progression suggesting that 
specific inhibition by soluble EphA3 may be 
therapeutically useful. 
The IIIA4 monoclonal antibody originally raised 
against LK63 human acute pre-B leukemia cells and 
used to affinity isolate EphA3 binds the native EphA3 
globular ephrin-binding domain with sub-nanomolar 
affinity (KD ~5x10-10 mol/L). Like ephrin-A5, pre-
clustered IIIA4 effectively triggers EphA3 activation, 
contraction of the cytoskeleton, and cell rounding. 
Moreover, radio-metal conju-gates of ephrin-A5 and 
IIIA4 retain their EphA3-binding affinity, and in mouse 
xenografts localise to, and are internalised rapidly into 
EphA3-positive, human tumours. 
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